Microvascular Therapeutics: Funding, Investors & Team (Sep 2026)
Microvascular Therapeutics has invented MVT-100, a novel ultrasound contrast agent with a patented design. This agent's neutral surface chemistry renders it suitable for the creation of molecular imaging agents and image-guided therapy. With its neutral surface chemistry, Microvascular Therapeutics-100 has the potential to be utilized in the development of molecular imaging agents and image-guided therapy. The company has also devised an expedited path for development, which could ultimately result in the approval of MVT-100 specifically for echocardiography purposes.
Microvascular Therapeutics has raised $4.0M across 3 funding rounds on record, the most recent an undisclosed round of $4.0M announced in Oct 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Microvascular Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Microvascular Therapeutics Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
Microvascular Therapeutics announced a Grant in Apr 2022; the amount was not disclosed.
7 months later, an undisclosed round was announced in Nov 2022 with no disclosed amount.
11 months later, an undisclosed round of $4.0M was announced in Oct 2023.
Microvascular Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Microvascular Therapeutics Funding Compared to Other Biotechnology Startups
Microvascular Therapeutics' latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Microvascular Therapeutics in Biotechnology and Tucson
Companies Similar to Microvascular Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Microvascular Therapeutics Funding FAQs
What does Microvascular Therapeutics do?
Microvascular Therapeutics has invented MVT-100, a novel ultrasound contrast agent with a patented design. This agent's neutral surface chemistry renders it suitable for the creation of molecular imaging agents and image-guided therapy. With its neutral surface chemistry, Microvascular Therapeutics-100 has the potential to be utilized in the development of molecular imaging agents and image-guided therapy. The company has also devised an expedited path for development, which could ultimately result in the approval of MVT-100 specifically for echocardiography purposes.
How much funding has Microvascular Therapeutics raised?
Microvascular Therapeutics has raised $4.0M across 3 rounds on record. The most recent is an undisclosed round of $4.0M announced in Oct 2023.
When did Microvascular Therapeutics last raise funding?
Microvascular Therapeutics' most recent funding round on record is an undisclosed round of $4.0M, announced in Oct 2023.
Who is the CEO of Microvascular Therapeutics?
Evan C Unger is listed as CEO at Microvascular Therapeutics.
Where is Microvascular Therapeutics headquartered?
Microvascular Therapeutics is based in Tucson, Arizona, United States.
How many employees does Microvascular Therapeutics have?
Microvascular Therapeutics is in the 1-10 employee band.
How does Microvascular Therapeutics' funding compare to other Biotechnology startups?
Microvascular Therapeutics' latest round of $4.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Microvascular Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Microvascular Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.